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1. Introduction  
Gene therapy is defined as the transference of nucleic acids to somatic cells of an individual 
resulting in a therapeutic effect (Yla-Herttuala & Martin, 2000). Among the advantages of 
gene therapy over the existent modalities of treatment are: the selective treatment of affected 
tissues, the possibility of using locally endogenous proteins in cases where its systemic 
application would incur in serious adverse secondary effects, and the possibility of 
therapeutic effects in the long term after a single application (Yla-Herttuala & Alitalo, 2003).  
Despite medical advances in the last 30 years, cardiovascular diseases (CVD) constitute the 
main cause of death on the developed world. Ischemic Heart Disease (IHD) is one of the 
main morbidities in an ageing population. Over 5 million Americans are believed to have 
symptomatic Heart Failure (HF), and every year ~0.5 million patients are diagnosed, with a 
prevalence of 0.5-2% of the general population; the estimated direct and indirect costs of HF 
in the United States is ~$30 billion. HF is a disabling chronic disease and the most frequent 
discharge diagnosis for hospitalization among older adults. Despite the significant resources 
for its treatment, outcomes remain poor. The five-year survival for individuals diagnosed 
with HF is less than 50%, and in end-stage HF one-year survival may be as low as 25% 
regardless of medical therapy, which constitutes one of the dimmest prognosis compared 
with of any malignant disease, with the exception of lung and pancreatic carcinomas (Levy 
et al., 2002; Lloyd-Jones et al., 2002). 
HF constitutes the end stage of most CVD, it has become one of the most researched fields in 
the last 10 years, with significant advances to understand its key mechanisms; and today 
presents a great challenge to modern medicine, because of its persistent high mortality and 
increasing incidence. This can be attributed partially, to the absence of therapies that are 
focused on the key molecular basis of the disease, although the therapeutic approach has 
improved in last the two decades, existing treatments are not ideal due to its broad scope 
and do not have a significant impact on the overall mortality, since they are not sufficient to 
support to the myocardium performance and to increase the global cardiac function. It is for 
this reason that new therapeutic approaches are required, focused to correct the molecular 
defects of HF.  
Among the molecular defects observed during HF, that have been explored as therapeutic 
targets, are the alterations in Ca2+ handling during the excitation-contraction coupling 
(Hoshijima et al., 2002; Iwanaga et al., 2004; Kaprielian et al., 2002; Michele et al., 2004; 
Miyamoto et al., 2000; Most et al., 2004b; Most et al., 2007; Pleger et al., 2007; Pleger et al., 
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2005; Szatkowski et al., 2001), alterations in the ┚-adrenergic receptors and their interaction 
with G proteins (Jones et al., 2004a; Koch, 2004; Maurice et al., 1999; Munch et al., 2005; 
Tevaearai et al., 2002), alterations of cellular signaling, including the members of the protein 
kinase C (PKC) family (Hambleton, 2006), and to the production of second messengers by 
the enzyme adenylyl cyclase (Lai et al., 2004). The apoptosis of cardiac myocytes also has 
been mentioned (Chatterjee et al., 2002; Tenhunen et al., 2006). Finally, the use of over-
expressing angiogenic factors, also has been analyzed as alternatives in patients with HF 
secondary to ischemic cardiomyopathy.  
As a therapeutic strategy for CVD, gene therapy is a field that during the last decade has 
experienced a substantial increase in research. Some diseases like hypertrophic 
cardiomyopathy, have a clear-cut genetic basis, arrhythmogenic right ventricular dysplasia, 
and as such constitute a theoretically obvious target. Nevertheless, gene therapy can also be 
used to normalize the expression of genes that undergo down regulation in pathological 
ventricular hypertrophy, where the cardiac myocyte responds to a physiological tension, 
such a pressure or volume overload, by means of the activation of a fetal genetic program, 
with a subsequent downgrade of performance, thus starting a deleterious cycle, with further 
deterioration of cardiac function, as observed in HF. The hypertrophic response is associated 
with a decrease of gene expression of several key proteins, such α− and β−myosin heavy 
chains, the Ca2+-ATPase pump of the sarcoplasmic reticulum (SERCA2a) and its regulatory 
protein phospholamban (PLB), and the S100A1 regulatory protein.  
There are diverse strategies used for the treatment of HF, mainly constituted by 
pharmacological therapy that it is mainly focused on a neurohormonal blockade; further 
treatment can be offered with more invasive therapies such as cardiac re-synchronization; 
mechanical unloading with different surgical strategies and the use of left ventricular assist 
devices, which can induce myocardial remodeling at the molecular level normalizing gene 
expression. Currently the only definitive strategy for treatment of end stage HF is cardiac 
transplantation.  However, despite of the advances in the treatment of HF with the addition 
of new drugs and very effective devices, the number of patients with HF is increasing 
(Hamad et al., 2007). Without a great scale effective strategy, regenerative medicine 
including stem cells and gene therapy could provide with a solution to an increasing 
number of patients currently without a therapeutic option. 
While most of the research of gene therapy in CVD has been for HF; it is not limited to 
normalize the expression of down regulated genes, it also offers the possibility of 
modulating inflammatory and angiogenic mediators, which have a key role in several other 
CVD. Ischemic heart disease continues to be one of the main causes of mortality in the 
developed world, and while the treatment by medical, interventional and surgical options, 
has greatly decreased the morbidity and mortality associated, there is still a subset of 
patients that cannot be successfully treated with the current therapeutic options. Thus 
therapeutic angiogenesis in ischemic myocardium, mediated by gene therapy may also be 
an option in a clinical setting. As mentioned the treatment by interventional cardiology 
(PTCA) and surgery (CABG), are highly effective strategies, both with some long term 
drawbacks, specifically intra-stent restenosis in the former, and vein graft disease in the 
later. In both cases gene therapy may provide a key role to enhance, already very successful 
therapies. For example, transient, nonintegrative gene expression has been shown to be 
sufficient to promote neovascularization in the case of angiogenesis. This may also apply to 
antiproliferative strategies for the prevention of neointima formation in patients that 
received PTCA, for the prevention of intra-stent restenosis, or for inhibition of 
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atherosclerosis in venous and arterial grafts. Because cardiovascular diseases are diverse 
and as such have unique traits, they require precise tailoring of gene therapy strategies for 
particular disease. Those features, which may vary include mode of delivery, type of vector, 
length of gene expression, and target tissue. The angiogenic factors that have been object of 
a more exhaustive study are the vascular endothelial growth factor (VEGF) and the 
fibroblast growth factor (FGF). These cytokines can be administered in the form of 
recombinant protein or of the genes that they codify for these proteins. Each of these 
approaches presents a series of advantages and disadvantages that are being investigated in 
detail, in animal models and in clinical tests with humans; and may also become options in 
the clinical setting in a not so distant future. 
Another exciting new target for gene therapy are the electrical and rhythm disturbances in 
the heart. While a number of tachy-arrhythmias have a clear genetic origin in channel 
protein mutations, or calcium modulating proteins, these monogenetic arrhythmias, may 
only benefit a small number of patients, but current research has shown encouraging results 
in the treatment of bradi- and tachy-arrhythmias of multifactorial origin, and also in atrial 
fibrillation. 
In the last decade a significant number of molecular mechanisms have been identified as the 
molecular basis of HF (Yla-Herttuala & Alitalo, 2003). Likewise the possibility of perform 
transference of genomic material in vivo, has been made possible exploring this technique as 
an option to correct the defects present in CVD, under the premise of being a therapy able to 
correct the underlying defects present in the failing heart.  
Although the treatment by transference of genetic material still presents many challenges, 
small clinical tests have already been performed, applying angiogenic factors in ischemic 
cardiomyopathy (Hedman et al., 2003; Kastrup et al., 2005; Stewart et al., 2006). In relation to 
other molecular mechanisms of the HF, as it is mentioned below, several of them are in 
clinical phases in different stages of proximity to a wider clinical setting. The potential that 
has this new therapeutic option, combined to the novelty of its mechanism of action, makes 
imperative that its advantages and disadvantages are known to be able to take advantage of 
this emergent therapeutic option.  
During the late 1990s and early 2000s, gene therapy for CVD, experienced a significant 
expansion, searching for targets that could benefit a large number of patients; while the 
results where promising on experimental models, these were not translated to the clinical 
setting. This added to the rising of stem-cell research, resulted in an abandonment of the 
field, however with the increasing data identifying the molecular basis of HF, it has become 
clearer that a “silver bullet“ is not feasible and a more combinatorial approach may be 
required. Thus the field of gene therapy has experienced a rebirth in the last years. Evidently 
an ideal gene therapy depends on the underlying cause of HF, and as such a multistep 
approach may be required. For example, when utilizing gene therapy for the most common 
cause of HF which is IHD, it may be needed to target endothelial cells to manage the 
atherosclerotic plaques and induce angiogenesis, providing means to inhibit apoptosis of 
hibernating myocardium, and long term inotropic support, reducing cardiac remodeling 
and reducing risk of arrhythmias. This approach clearly illustrates that a “one size fits all” 
approach is impossible, and that manipulation at several levels is needed, in most cases 
gene therapy would be needed to over-express target molecules, modifying of intracellular 
signaling, loss of function by the use of dominant negative molecule or introducing siRNA, 
correction of mutations in the genome; and also combine with cellular therapy by 
introducing genetically modified cells (Vinge et al., 2008). In 2010, the number of gene 
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therapy clinical trials for CVD in the world was 144, representing 8.5% of the total, 
occupying the second place after gene therapy for cancer diseases that represented 64.5% of 
all ongoing gene therapy trials. 
Therefore, it becomes clearer that the possibility that by gene therapy, we could improve the 
cardiovascular function through a normalization and/or modulation of gene expression in 
the near future is one of the most promising and active clinical investigation goals in the 21st 
century. The purpose of this chapter, is to review the current status of the literature in the 
basic and clinical settings, and analyze future perspectives for cardiovascular gene therapy.  
2. Vectors used for cardiovascular gene therapy 
The initial tests to transfer genetic material into the heart were done using plasmid DNA, 
chosen by its easy production and security. Although the first studies showed positive 
results (Fortuin et al., 2003; Tsurumi et al., 1996), in randomized larger tests, where genes 
coding for vascular endothelial growth factor (VEGF) as well other angiogenic factors were 
transferred, they showed that due to its very low efficiency was not a useful technique 
(Kastrup et al., 2005). The use of cationic liposomes in the transference of genetic material in 
cells in culture, does not increase the efficiency of transference in vivo (Laitinen et al., 1997; 
Wright et al., 2001). One of the main problems with the use of plasmid DNA, is the lack of 
response with an increasing dosage (Rutanen et al., 2004). The use of this vector, is 
considered relatively safe, but it has demonstrated in animal models that it can produce 
fever, inflammation and infarcts in the skeletal muscle and in the myocardium (Hedman et 
al., 2003). DNA and RNA oligonucleotides potential to be used as decoys, were mentioned 
over 10 year ago, but their minimum effectiveness in tissues, also discards them for some 
clinical application (Alexander et al., 2005). Due to above factors the viral vectors can be a 
better option for cardiovascular gene therapy (Table 1).  
Small interference RNA (siRNA) is a useful tool to down-regulate the expression of genes in 
vitro, but as an isolated technique has proven to be inefficient in the preclinical and clinical 
setting; thus it was discarded over 10 years ago, as a viable option. However in the recent 
years its combination with viral vectors has reignited the interest on this strategy; and it 
may become a key tool for inhibiting the expression of genes with deleterious effects (Poller 
et al., 2010; Suckau et al., 2009; Yang et al., 2010). 
Among the viral vectors, the retrovirus were the initial choice, because of the limited 
immune response generated and the possibility of a sustained expression (years), 
nevertheless, the retrovirus have several disadvantages for its use on CVD, including low 
efficiency of infection, limited cardiac tropism because they infect mainly dividing cells; and 
also concerns in their safety have been mentioned due to the oncogenic potential (Laitinen et 
al., 1997). Because of this reasons it is a vector in which the interest has decreased. Recently, 
lentivirus have been used mainly to transfer genetic material to cells of the vascular wall, 
they have demonstrated a high efficiency of infection in smooth muscle and elicit a 
minimum immune response, nevertheless, the tropism for myocardium is limited and its 
production in great amounts is difficult, thus currently is not a viable option and requires 
engineering of this vector to improve its utility on a large scale, facilitating its production 
(Kankkonen et al., 2004). Sendaivirus and herpesvirus, have been mentioned as possible 
useful vectors, but sufficient data to this date does not exist on their utility (Masaki et al., 
2001). Currently the adenovirus (Ad), and the adeno associated virus (AAV), are the most 
studied vectors in the cardiovascular gene therapy, since both have demonstrated a great 
effectiveness in cardiac muscle, the vascular wall and the liver (Wright et al., 2001). 
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Vector Advantages Disadvantages 
Naked plasmid DNA 
Easy to produce. 
Safe. 
Temporary 
expression. 
Low transfer rate. 
Adenovirus 
High transfer rate. 
Easy to produce substantial 
quantities. 
Transfer to quiescent cells. 
Big size transgene (7-30 kb). 
Multiple cell type tropisms. 
Immune response, 
dose dependent. 
Temporary 
expression. 
Adeno associated virus 
(AAV-1, 2, 5, 6, 8, 9) 
Long-term expression. 
Moderate immune response. 
Transfer to quiescent cells. 
High tropism for skeletal 
muscle (AAV-1, -6) and cardiac 
(AAV-8, -9). 
Do not produce diseases in 
humans. 
Limited transgene 
size (5 kb). 
High yield 
production 
difficulties. 
Retrovirus 
Long-term expression. 
Minimal immune response. 
 
Low transfer rate. 
Non-controlled 
integration to 
genome. 
Limited tropism. 
Transfer only on 
dividing cells. 
Antisense oligonucleotides, 
siRNA 
Easy to produce. 
Limited in vivo 
efficiency. 
Requires high 
transfer rate. 
 
Table 1. Vectors used in Cardiovascular Gene Therapy. 
The first generation Ad, have a very high initial expression, reaching their maximum effect 
in the first days after the material transference, but the expression is diminished after 
approximately 2 weeks (Poliakova et al., 1999; Rissanen et al., 2003; Rutanen et al., 2004). 
Therefore they seem to be useful when a high expression is required for a limited amount of 
time, like in therapeutic angiogenesis for wounds. The repeated administration of Ad for 
gene therapy is not useful in great mammals, since it evokes an important immune 
response. Small doses of Ad produce a minimum inflammatory response in the 
myocardium. The second and third generation Ad, produce a smaller immune response and 
seem to have a prolonged expression, but its utility in gene therapy trials in humans is not 
yet known (Wen et al., 2004). The security of the Ad has demonstrated to be very high in 
clinical trials, being the fever the most important complication.  
The AAV have a number of characteristics that makes them potentially useful for cardiac 
gene therapy, they have a natural tropism towards vascular smooth muscle, skeletal muscle 
and myocardium (Gruchala et al., 2004). They are able to express genes in quiescent cells 
like Ad, and for a long period of time, although the maximum expression is reached in days 
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(Su et al., 2004). Because they do not produce diseases in the human, the inflammatory 
response that they generate is minimum; the native AAV are able to integrate themselves to 
the human genome, but modified AAV vectors cannot, and maintain their long term 
expression by means of episomal associations with the genomic DNA, thus reducing the risk 
of mutagenic and oncogenic insertions, a threat that at least theoretically is present with 
other vectors of long term expression like the retrovirus (Schnepp et al., 2003). In murine 
and rodent models single stranded (ss) AAV6, self-complementary (sc) AAV6 and ssAAV9 
are capable of long term expression after transference of genetic material to the 
cardiomyocytes, however it has not been reproduced in large animals. Recently it has been 
proposed that the highest levels of expression in large animals, are obtained using scAAV6 
vectors, delivered through surgical methods (White et al., 2011). 
3. Routes of administration 
The transference of genetic material to the heart can be obtained by three different routes, by 
intravascular transference, ex-vivo transference, and by intra-organ injection, in the 
following sections we describe in more detail these routes.  
3.1 Intravascular transference  
For the intravascular transference, different systems using catheters have been developed to 
improve penetration of the vectors through the intima vascular layer. Nevertheless the 
transference in vascular athrosclerotic injuries with calcifications, deposits of cholesterol, 
infiltrated and continuous inflammation are a significant obstacle to achieve satisfactory 
transfer (Laitinen et al., 1998). The use of porous stents, in which the vectors with 
therapeutic genes can be eluted, has been proposed as an option to improve the 
transference, but currently has not been sufficiently explored (Sharif et al., 2006; Walter et 
al., 2004). The ideal route of administration for gene therapy is an intravenous vector, but 
the required amount of virus to obtain an optimal expression in great mammals, is probably 
very high to consider it safe for humans.  
3.2 Ex vivo transference 
The ex vivo administration is a combination of the cellular therapy and gene therapy, it 
consists of the administration of the test-tube vector, to isolated stem cells from the bone 
marrow, or cultures of skeletal myoblasts, with the intent of later transferring these cells 
transformed with the transgenes into the patient (Assmus et al., 2006; Dib et al., 2005; Haider 
et al., 2008; Haider et al., 2007; Nasseri et al., 2007; Sim et al., 2007; Smits, 2004; Yau et al., 
2005; Ye et al., 2005). This form of administration has been studied mainly in the expression 
of angiogenic factors, and cytokines (Assmus et al., 2006; Haider & Ashraf, 2008; Ye et al., 
2005). Among the advantages of this form of administration it is the possibility of using 
efficient methods for the transference of genetic material, like cationic lipids or 
electroporation, that are not possible to use in the whole subject, and which in addition the 
location of the modified cells in the heart, has a localized, continuous expression and with 
constant levels, without systemic effects (Haider & Ashraf, 2008; Sim et al., 2007; Smits, 
2004). The cardiomyocytes are by nature resistant to the transference of genetic material, and 
this form of administration avoids this complication. The ex vivo administration, has the 
potential to become a very useful tool, but at present it depends on stem cell research and 
their differentiation to the cardiac phenotype, so that it can be explored widely and to know 
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its potentials and limitations. One of the major drawbacks with this route of administration 
is the location of the transferred cells to the patient. The intramuscular injection of ex vivo 
transformed cells to express the gene of interest has been mentioned, but the little 
distribution of the transferred cells has made difficult its use (Lee et al., 2000; Springer et al., 
1998).  
3.3 Intra-organ transference 
The administration by intra-myocardial injection, at present it is considered the most 
efficient form to obtain the desired expression in the cardiac tissue, but it as has been 
reported the administration of a high volume of vector to obtain an expression, can be 
associated with a local injury and alterations in the structure of the myocardium wall 
(Kastrup et al., 2005; Rutanen et al., 2004; Vale et al., 2001). Different studies have 
demonstrated that the intra-arterial route is of little effectiveness unless the permeability of 
the endothelial lining is increased, or a high pressure gradient is used; in these cases a 
problem to consider is the increased tissue distribution and ectopic expression of the 
transferred gene (Lee et al., 2000; Rissanen et al., 2003; Wright et al., 2001). In animal models 
the most used techniques include the use of percutaneous devices, one is known as the 
antegrade epicardial coronary artery infusion, where the left main coronary artery is 
catheterized, simultaneously with the coronary sinus, isolating the coronary circulation by 
means of an oxigenator and a extracorporeal pump, where the solution with the vector is 
added and circulated through the coronary circulation continuously for the desired time 
(Kaye et al., 2007). This system is known as “V-Focus”, and has shown satisfactory results in 
larger animal models. Another system which employs percutaneous devices, is the 
percutaneous antegrade myocardial gene transfer, in this system the left anterior coronary 
artery (LAD) and the circumflex artery are catheterized, while the great cardiac vein or the 
anterior descending vein are catheterized, when the vector is infused through the arterial 
catheters, a balloon is inflated in the venous catheter, thus creating a high pressure gradient 
for up to three minutes (Hayase et al., 2005). The system in which the greater effectiveness of 
transference has been observed, consist of perfusion of the myocardium by surgical 
methods, a technique known as Molecular Cardiac Surgery with Recirculating Delivery 
(MCARD); this consists in the establishment of conventional cardiopulmonary bypass, with 
isolation of the heart circulation and retrograde perfusion through the coronary sinus. 
MCARD allows performing surgical procedures in the heart while the transference of 
genetic material is occurring (Hayase et al., 2005; Katz et al., 2010; Raake et al., 2004; White et 
al., 2011). An option to avoid the ectopic expression of the transferred gene is to put the 
expression of the transferred gene under the control of a specific cardiac promoter, as is the 
case of the human cardiac calsequestrin gene (hCasq2) (Reyes-Juarez et al., 2007). At the 
moment, in our laboratory we are developing adenoviral vectors that contain the promoter 
of the gene hCasq2 and direct the expression of the calcium pump SERCA2a in specific form 
for the cardiac myocytes (unpublished results). 
4. Heart failure: therapeutic targets  
As it was mentioned briefly in the introduction, one of the main advantages of gene therapy 
as a therapeutic option is the possibility of modifying key molecular defects that are present 
in the failing heart. In the last years the knowledge of the molecular basis of HF has 
advanced significantly, and today multiple alterations that exist in the continuum of the 
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natural history of HF are known. Although there is not an integrative model that is able to 
ensemble the multiple alterations described in HF (Braunwald & Bristow, 2000), due to 
multiple etiologies, the existing data allows us to identify targets for gene therapy. In the 
following sections we describe the different approaches that are being explored to treat 
cardiovascular diseases. 
4.1 Alterations in calcium handling  
Without doubt the area of greater interest in the molecular mechanisms of HF, are the 
alterations on the regulation of the concentrations of Ca2+ during the process of the 
excitation-contraction coupling, which have been demonstrated to play a critical role in the 
decreased contractile properties of the myocardium. Among the involved alterations are 
changes in the levels of the expression of regulatory proteins that act as sensors of the 
intracellular Ca2+ concentrations (Kaprielian et al., 2002).  
These alterations include decreased levels of the sarcoplasmic reticulum Ca2+-ATPase 
(SERCA2a), with a subsequent decrease of the recapture of Ca2+ to the sarcoplasmic 
reticulum (SR) during diastole, resulting in a smaller amount of Ca2+ available to be released 
in the following contraction cycle. The decrease of the functional levels of phosphorylated 
phospholamban (PLB), a regulator of the activity of SERCA2a, causes the activity of 
SERCA2a to be decreased during HF; this decrease is not only due to a smaller expression of 
the SERCA2a protein, but to alterations in the level of phosphorylation of PLB as a result of 
an increase in the levels of the members of the family of the protein kinase C (PKC), which 
phosphorylates the inhibitor of phophatase-1 (PP1), activating it, which causes a 
dephosphorylation of PLB. The Ca2+ release channel of the SR (Ryanodine Receptor, RyR), 
has been reported in an unstable state, dissociated of the protein calstabin, which results in a 
higher probability of opening of the channel, and spontaneous liberations of Ca2+ appear 
during diastole (diastolic leak) which are associated with ventricular arrhythmias and more 
importantly with a decrease of the reserve of Ca2+ available for contraction (Bers et al., 2003; 
Braunwald & Bristow, 2000; Yla-Herttuala & Alitalo, 2003).  
The existing reports have focused to the correction of these defects; the therapeutic targets 
include the increase of the expression of SERCA2a, or blockade the expression of their 
regulator PLB, the regulatory protein S100A1, and parvalbumin in order to make more 
efficient the cardiac relaxation. In the following pages each of these strategies is detailed.  
4.1.1 The sarcoplasmic reticulum Ca
2+
-ATPase and phospholamban 
The calcium pump SERCA2a has a fundamental role in the normal myocardium function 
during muscular relaxation, recapturing the majority (75%) of the released Ca2+ from the SR 
for contraction, and reloading the SR maintaining an amount of Ca2+ that is sufficient to 
achieve an optimal contraction. Due to this role it is a central point of the molecular basis of 
HF; where its expression is regulated in a negative manner, diminishing the capacity to 
reload the SR with Ca2+ after each contraction, resulting in a deficient contraction due to lack 
of Ca2+ inside the SR (Kaprielian et al., 2002). In the last years the expression of SERCA2a, 
became one of the most explored pharmacological targets in basic research, and to a lesser 
extent in clinical investigation and, although without conclusive positive results obtained 
(Zarain-Herzberg & Rupp, 2002; Zarain-Herzberg et al., 1996). The use of gene therapy, to 
over-express SERCA2a, has the advantage of eliminating the associated effects of drugs 
used to increase the expression of SERCA2a (Gianni et al., 2005).  
In similar way that the induction of SERCA2a expression has been extensively explored by 
pharmacological means, the over-expression by transference of genetic material, also has 
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been analyzed in vitro and in vivo. Over-expression of SERCA2a improves the contractile 
function and the energy consumption in animal models with HF, improving the thickness of 
the anterior wall, and reducing ventricular arrhythmias. Other studies have also shown a 
decrease of inflammatory mediators and pro-apoptotic markers after transference of viral 
vectors overexpressing SERCA2a in pressure overload induced HF inhibition of ventricular 
remodeling in ischemic and volume overload induced HF; (Beeri et al., 2010; Mariani et al., 
2011; Miyamoto et al., 2000; Molina et al., 2010).  
Recent studies suggest that the failing heart is not refractory to treatment as was previously 
believed. For example, the observation that a small percentage of subjects with left 
ventricular assist devices (LVADs) can be permanently weaned from the device, strongly 
suggests that damaged hearts are capable of recovering lost function (Baba & 
Wohlschlaeger, 2008; Entwistle, 2003; Kuhn et al., 2004).  
Recently, in the United States a phase 2 clinical trial named CUPID (Calcium Up-Regulation 
by Percutaneous Administration of Gene Therapy in Cardiac Disease) of intracoronary 
delivery of AAV1/SERCA2a (MYDICAR®) to 39 patients with HF that started in 2007 was 
completed (Hajjar et al., 2008; Jaski et al., 2009). It was designed to evaluate the safety profile 
and biological effects of SERCA2a gene transfer; after 12 months follow-up, the patients 
showed an acceptable safety profile, and improvement of the functional class. There was no 
increase in adverse effects, disease-related events, laboratory abnormalities or arrhythmias. 
Currently, there are two other ongoing gene therapy clinical trials to express SERCA2a in 
the hearts of patients with HF using AAV6/SERCA2a; one in England and one in France. 
Therefore, the transfer of SERCA2a cDNA into cardiomyocytes is a promising approach to 
treat HF by gene therapy (Table 2). 
In transgenic mice overexpressing SERCA2a subjected to ascending aortic constriction, the 
down-regulation of SERCA2a protein in hypertrophic hearts was prevented, however, the 
hearts showed no increase in inotropic response compared to the wild type mice 
hypertrophic hearts, suggesting that energy supply may be a limiting factor for the benefit 
of SERCA2a overexpression in hypertrophied hearts (Pinz et al., 2011). Therefore, it should 
be considered novel strategies combining energetic support with increasing SERCA2 
activity might improve the therapeutic effectiveness for HF. 
Closely related to SERCA2a is phospholamban (PLB), a peptide of 52 amino acids, that has a 
role as a regulator of the function of SERCA2a, inhibiting the pump in its native state, and 
dissociating from the pump when is phosphorylated by the protein kinase A (PKA), 
increasing the velocity of transport of Ca2+ by the enzyme. During HF, the SERCA2a/PLB 
ratio is diminished to a great extent by the diminution of SERCA2a, which causes that the 
amount of SERCA2a that is dissociated of PLB diminishes and with this its activity and 
capacity to recapture the Ca2+, released during the contraction (Hoshijima et al., 2006).  
The most used strategy of gene therapy that involves PLB, consists of the transference of a 
peptide that codifies for a pseudo-phosphorylated mutant of PLB, which imitates the 
conformational changes induced by phosphorylation, and competes with the native form of 
PLB, increasing the activity of SERCA2a (Hoshijima et al., 2002). The tests realized in animal 
models have used AAV vectors, and followed the evolution up to 6 months after the 
transference of genes. In animals with HF subjected to gene therapy with the PLB mutant, 
an improvement of cardiac function is observed, delaying the advance of HF, and 
approaching near normal levels, corroborated by hemodynamic values, besides this strategy 
prevents the remodeling of the cardiac wall and it even reverts the changes observed in HF, 
decreasing fibrosis (Iwanaga et al., 2004). Like in the case of S100A1 mentioned below, the 
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expressed fetal phenotype observed during HF reverts to the adult phenotype of the normal 
heart, thus improving its metabolism.  
In the last few years, the use of siRNA molecules to down-regulate the expression of PLB, 
and improving the SERCA2 function has been explored with promising results in rat models 
in the short and medium term. As mentioned previously isolated siRNA is of little use in a 
clinical setting, thus it needs to be transferred with a viral vector, AAV9 was used in the 
experimental models with good results. PLB siRNA improves myocardial function by 
means of increasing the activity of SERCA2a in a pressure overload model in rats (Suckau et 
al., 2009; Tsuji et al., 2008). A cautionary note must be made when the choice is made to 
target PLB in HF, it is well documented that the knockout or continuous blocking expression 
of PLB results in cardiomyopathy and HF, thus the use of PLB as a target in gene therapy 
must be strictly controlled so that once the desired effect of restoring the heart to a correct 
function, the inhibition of PLB function and/or expression can be modulated, to avoid 
secondary effects (MacLennan & Kranias, 2003; Shanmugam et al., 2011). 
Another strategy that involves PLB, is the inhibition of PP1, the enzyme responsible of 
dephosphorylate it, keeping SERCA2a in an activated state (Nicolaou et al., 2009). 
Overexpressing the inhibitor-2 gene in a dilated cardiomyopathy hamster model, 
significantly reduced the activity of PP1, increasing the activity of SERCA2a with an 
improvement in the handling of intracellular Ca2+ concentrations, and consequently with an 
improvement of the cardiac function, as well as a diminution of the ventricular remodeling 
diminishing fibrosis significantly (Yamada et al., 2006). The above studies indicate that gene 
therapy directed towards PLB or its regulation, is an area that can in the future be of 
importance, but requires further research with more studies in HF models, to be able to 
reach a phase of clinical investigation. 
4.1.2 The S100A1 protein 
The S100A1 protein is a member of the S100 family, binding Ca2+ and has an “EF-hand” 
domain. The members of this family are involved in several functions, among them signal 
transduction, control of the cellular cycle, interactions with the cytoskeleton, cellular 
differentiation. It has an important role in the function of the striated muscle; it is 
abundantly expressed in muscle tissue, particularly in cardiac muscle, where it co-localizes 
with SR and contractile filaments. Its expression is affected negatively during HF secondary 
to cardiomyopathies (Most et al., 2001; Most et al., 2004a). It has been demonstrated that 
S100A1 has a positive inotropic and lusitropic effect in the heart. The inotropic effects are 
due to the interaction with SR and its components, particularly SERCA2a, increasing its 
activity, thus promoting the recapture of Ca2+ during the relaxation of the myocardium, 
increasing the amount of Ca2+ available to release during the next contraction cycle, which is 
directly related to the contraction force. It also interacts with RyR, stabilizing it and 
diminishing the diastolic leak of Ca2+ (Most et al., 2001; Most et al., 2004a). These data 
indicate that S100A1 is involved in two of the key molecular processes of HF, added to the 
fact that its expression falls in HF, turns it into an objective of great value to explore.  
In vitro tests have demonstrated that the over-expression of S100A1, improves the contractile 
function of the cardiomyocytes by means of the mechanisms before mentioned (Most et al., 
2004b; Pleger et al., 2005). In animal models of HF, the S100A1 over-expression has been 
proven to be enough to preserve the myocardial function after an acute infarction, and to 
prevent the appearance of HF (Most et al., 2004b; Most et al., 2007). Recent reports using 
AAV have followed these models for prolonged periods (20 weeks), where it has been 
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observed that the S100A1 over-expression improves the myocardium function in sustained 
form, and in an independent and synergic effect to the treatment with ┚-blocker agents 
(Pleger et al., 2007), restoring the sensitivity of the myocardium to ┚-adrenergic agonists, 
that usually is very decreased in HF. In these models, over-expression of S100A1 is able to 
revert the phenotype of HF expressed by the myocardium, returning after two months to 
the normal pattern of the adult cardiac muscle, in similar form to that observed in patients 
with HF awaiting cardiac transplant, with devices of left ventricular assist, who can be 
weaned from the device after a prolonged period with a significant improvement of cardiac 
function (Entwistle, 2003; Kuhn et al., 2004). The available data, indicate that S100A1 is an 
important therapeutic target, but further research is needed before it can be used in a clinical 
or pre-clinical setting (Rohde et al., 2010). 
4.1.3 Parvalbumin 
Diastolic dysfunction is a component associated to HF, found mainly in patients older than 
65 years; currently specific treatments for this type of dysfunction do not exist. In cardiac 
myocytes obtained of these patients it is observed that the required time to remove Ca2+ 
from the cytoplasm is increased; this slows down the relaxation of the heart and jeopardizes 
the filling of the cardiac chambers for the following beat. Parvalbumin is a soluble 
intracellular protein of low molecular weight, with capacity to bind Ca2+, which is expressed 
importantly in fast-twitch skeletal muscle, but it is not expressed natively in the heart. Its 
main function is to accelerate the rate of decrease of the intracellular Ca2+ in an ATP-
independent manner. The gene therapy interventions that involve parvalbumin, to this time 
have been limited to in vitro studies and to animal models followed by short terms of time 
(one week), these tests have demonstrated that the expression of parvalbumin in the heart, is 
associated with an increase of the speed of relaxation. The data can be used as the basis to 
express parvalbumin in the heart, by means of AAV vectors, to evaluate its effects in the 
long term. Although the effects that are obtained expressing parvalbumin in the heart are 
very similar to the observed ones with over-expression of SERCA2a, the ones obtained with 
parvalbumin do not require of ATP, avoiding compromising even more the energetic needs 
of the heart. Due to this, parvalbumin constitutes a therapeutic target that must be further 
explored in the future (Michele et al., 2004; Szatkowski et al., 2001).  
4.2 β-Adrenergic system  
Alterations of the ┚-adrenergic receptors during HF have been described extensively, 
including a decreased density of receptors in the myocardium, to desensitization to ┚-
agonists. The desensitization of the receptors explains to a great extent the refractory 
response to the treatments directed to the adrenergic routes. The ┚-adrenergic receptors are 
coupled to G proteins that are regulated by protein kinases of receptors coupled to G 
proteins, known in the case the adrenergic receptors (Beta Receptor Adrenergic Kinase) 
┚ARK1 and ┚ARK2, the expression of the two enzymes is up-regulated during HF and it 
plays a key role on the desensitization of the ┚-receptors (Koch, 2004). Transgenic mice with 
over-expression of the ┚1-receptors develop cardiomyopathy, whereas in animals that over-
express ┚2-receptors contractility is increased without developing any pathology.  
In animal models it has been demonstrated that the overexpression of ┚2-receptors directed 
to the cardiac tissue, is associated with an increased contractility and a greater response to 
isoproterenol (Jones et al., 2004a; Maurice et al., 1999; Tevaearai et al., 2002). In mice that 
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over-express ┚ARK1 a contractility-diminished response to isoproterenol is observed. An 
inhibitor of ┚ARK1 has been developed, the transference of adenoviral vectors with 
┚ARK1ct in rabbits with acute infarct has been demonstrated to prevent the alterations in 
the ┚-adrenergic system, and improve the myocardial function and prevent the 
development of HF in short term basis (Koch, 2004). This same strategy was tested with 
AAV vectors to assess the long term effects, it improved the contractility, reversed 
ventricular remodeling and normalized the neuroendocrine axis, and intracellular 
adrenergic signaling, interestingly this work shows that addition of adrenergic antagonists, 
was not additive to the gene transfer, but treatment with pharmacological inhibitors yielded 
similar but less effective results (Rengo et al., 2009).  These data suggest that manipulation of 
┚ARK1 function has an impact on cardiac function, and that is susceptible to be 
manipulated by gene therapy.  
Another strategy used to modify the components of the ┚-adrenergic system by gene 
therapy, includes over-expression of the protein that re-uptakes norepinephrine in the heart 
(NE uptake-1). This protein is down-regulated during HF, which leads to an increase of 
extracellular catecholamine levels, resulting in a hyper-adrenergic state that it has a central 
role in the desensitization of the receptors. In rabbits with HF with an over-expression of the 
NE-uptake-1, the concentration of norepinephrine was kept near normal levels, and was 
associated with an improvement in cardiac function, and the cardiac hypertrophy was 
reverted, recovering the normal phenotype of the heart (Munch et al., 2005).  
4.3 Intracellular signaling  
In the pathogenesis of HF, the hyper-adrenergic state and the alterations in the intracellular 
concentrations of Ca2+ contribute to alter the activation of different intracellular signaling 
pathways, which turns them into potential targets for gene therapy. To this date, the 
adenylyl cyclase (AC), and the protein kinase C (PKC) have been explored as potential 
targets. The adenylyl cyclase is a key role molecule in the cardiac myocyte, particularly the 
type 6 (AC6) in animal models with HF is demonstrated that over-expression of the AC6 
improves the cardiac function and increase the life span. In pigs with established HF (Gao et 
al., 1999) besides improving the hemodynamic values, the cardiac function, and the 
response to isoproterenol, the over-expression of the AC6 prevents the remodeling of the 
cardiac wall and the appearance of fibrosis (Lai et al., 2004). It is thought that in the 
treatment of the HF response to AC6 is not only elicited due to an increase of the levels of 
cAMP, but it also modifies expression of other genes favoring the expression of useful genes 
for the myocardial contraction (Phan et al., 2007). There is an ongoing clinical trial, in which 
AAV5 encoding human AC6 is being delivered by intracoronary injection to patients with 
congestive HF (Table 2).   
There is evidence that damaged and inflamed tissues produce signals to attract stem cells to 
the injured tissue, and many of these signals have been identified including stromal-derived 
factor (SDF)-1. There has been growing evidence that the receptor of SDF-1 (CXCR4) 
participates in regulating myocardial repair after ischemic injury. SDF-1 has been shown to  
increase after myocardial ischemia, and several studies have shown that enhancing SDF-1 
levels around the infarct improves myocardial remodeling after infarction. Currently, a 
clinical trial is exploring the effects of percutaneous injection of SDF-1 naked DNA directly 
into the myocardium of patients with ischemic heart disease (Agarwal et al., 2010) (Table 2). 
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The other target for gene therapy that has been explored in the intracellular signaling setting 
is the family of the PKC, which is a component of several routes of transduction associated 
to the cellular membrane. The PKC┙ isoform is the most abundant in the heart where it 
plays a central role regulating the cardiac contractility. The lost of the contractile function in 
HF goes accompanied of an increase in the levels of PKC┙ in the heart. On this basis, studies 
have been performed in animal models transferring a dominant negative of PKC┙ by means 
of an adenoviral vector to determine their viability as therapeutic option. In rats with post-
infarction HF, the transference of a PKC┙ dominant negative improves myocardial 
contractility and improves the hemodynamic values (Hambleton, 2006; Palaniyandi et al., 
2009). While most of the research on the role and susceptibility of PKC as a therapeutic 
target has been done with conventional pharmacological therapy, the data show that at the 
very least is an option to be explored for gene therapy. 
4.4 Apoptosis  
It is well described that during the dilation of heart cavities observed in HF exists a 
remodeling of the myocardial wall, it has been proposed as one of the mechanisms 
responsible for this processes, the apoptosis of the cardiac myocytes. Although the precise 
mechanisms by which the apoptosis contributes to the remodeling of the myocardial wall 
are not understood, several studies have been realized using gene therapy to block apoptotic 
pathways with positive results. The Bcl-2 factor is able to block apoptosis, and it has been 
administered by means of an adenoviral vector after a period of myocardial ischemia in 
rabbits and it was found to avoid deterioration in the short and long term cardiac function, 
and also being able to prevent the dilation of the heart cavities and the remodeling of the 
same (Chatterjee et al., 2002). It was also demonstrated that prevents apoptosis in the border 
of the injured area; although has not determined if the expression of Bcl-2 is required at the 
initial moment of the injury or if it is required in the long term expression (Weisleder et al., 
2004). 
The protein p38 is a member of mitogen-activated protein kinases (MAPK) that is a 
fundamental regulator of growth, life span and cellular death. It has been reported that after 
myocardial infarction the activity of p38 falls, contributing to the development of apoptosis 
in the heart, increasing the downgrading of the function and the remodeling of the 
myocardial wall. When post-infarcted rats are treated with an adenoviral vector to over-
express p38, it prevents the deterioration of the myocardial function, has an anti-apoptotic 
effect, and avoids the fibrosis and remodeling of the ventricular wall (Bassi et al., 2008; 
Tenhunen et al., 2006). 
5. Therapy for heart failure of genetic causes  
Multiple causes of HF have been identified due to genetic mutations; nevertheless, it is 
known that these constitute a minimum percentage of the cases of HF. These causes involve 
several pathological mechanisms, mainly proteins of the sarcomere and the cytoskeleton 
(Bos et al., 2007; Chang et al., 2008; Karkkainen & Peuhkurinen, 2007; Lind et al., 2006; 
Ramaraj, 2008; van Spaendonck-Zwarts et al., 2008; Wiersma et al., 2007). Theoretically these 
causes of HF offer an immediate target for its treatment, since they are monogenic and have 
a direct pathological mechanism, and are isolated from the complicated networks involved 
in the regulation of other elements already mentioned. In this line of research, it has been 
demonstrated that when an exogenous sarcomeric protein is over-expressed it assembles to 
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Trial Target Gene Diseases Route/Vector Stage 
Num. 
patients 
CUPID 
SERCA2a 
(cardiac 
sarcoplasmic 
reticulum 
Ca2+ ATPase)
HF, ischemic 
and 
nonischemic
Intracoronary/AAV1-
SERCA2a (MYDICAR®) 
Phase 2, 
completed 
39 
SERCA2a 
Gene 
Therapy in 
LVAD 
patients 
SERCA2a 
Advanced 
HF with 
LVAD, 
ischemic and 
nonischemic
Intracoronary/AAV6 
Phase 2, 
enrolling 
16 
AGENT-
HF 
SERCA2a 
HF, ischemic 
and 
nonischemic
Intracoronary/AAV6 
Phase 2, 
enrolling 
30 
AC6 Gene 
transfer for 
CHF 
AC6 
(Adenylyl 
Cyclase-6) 
HF, ischemic 
and 
nonischemic
IntracoronaryAdenovirus
Phase 1/2, 
enrolling 
72 
Study to 
evaluate 
the safety 
of a single 
dose of 
ACRX-100 
in adults 
with 
ischemic 
HF 
SDF-1 
(Stromal-
Derived 
Factor-1) 
HF, ischemic 
only 
Intramyocardial/naked 
DNA 
Phase 1, 
enrolling 
16 
Table 2. Gene Therapy Clinical Trials for Heart Failure. 
form organized and stoichiometric complexes in the cytoplasm. The idea of this type of 
therapy is to displace the endogenous protein that has the defect, when changing the 
stoichiometry inside the cell. This type of therapy has not been explored experimentally, 
although it is susceptible to be done with animal models that reproduce hereditary 
cardiomyopathies.  
Mutations of larger proteins like dystrophin have also been identified as responsible in the 
genesis of muscular dystrophy of Duchenne, where several mutations have been described 
and it has even been proved to be caused by mutations that truncate the protein (Rodino-
Klapac et al., 2007). In these cases the possibility of being treated by gene therapy presents 
major technical difficulties, although it has been demonstrated that the transference of a 
mini-gene of dystrophin can improve the symptoms of the disease (Goyenvalle et al., 2004; 
Townsend et al., 2007).  
A phase 1 clinical trial of rAAV2.5-CMV-Mini-Dystrophin Gene Vector in Duchenne 
Muscular Dystrophy is in progress. This study investigates the safety and efficacy of the 
mini-dystrophin gene transferred to the biceps muscle for Duchenne muscular dystrophy 
patients, ages 5 to 12 years of age, using a recombinant AAV. The mini-dystrophin gene or a 
placebo agent (normal saline or empty viral capsids) is injected directly into both biceps 
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muscles while under conscious sedation. Following the gene transfer, patients are admitted 
to the hospital for 48 hours of observation followed by weekly outpatient visits. A bilateral 
muscle biopsy is performed following 6 weeks with long-term follow up will consisting of 
bi-annual visits for the next 2 years. 
6. Ischemic heart disease 
Atherosclerotic cardiovascular diseases continue to be the main cause of morbidity and 
mortality in the world. According to the American Heart Association the direct and indirect 
costs of coronary heart disease (CHD) for the year 2010 add up to 177.1 billion dollars. 
Pharmacologic therapies for CHD and HF have multiple systemic side effects and are pre-
disposed to several adverse drug interactions since polypharmacy is frequently involved in 
the treatment of such patients. Importantly, pharmacologic therapies aim to reduce 
symptoms and halt progression of disease but do not necessarily reverse the 
pathophysiology associated with CHD and HF. While revascularization procedures have a 
significant role in treating CHD, there are problems with this therapies further explained 
later, and frequently patients remain symptomatic despite maximal anti-anginal therapies 
and may require repeat revascularization procedures. While the obvious target for gene 
therapy in CHD is angiogenesis, one must keep in mind that there is a wide spectrum of 
mechanisms in its natural history, such as those of myocardial reperfusion injury during 
and after myocardial infarction (MI) and cell survival and apoptosis after MI, and during 
ventricular remodeling (Lavu et al., 2010). 
A significant part of the research in CHD has been focused on the administration of 
angiogenic growth factors, in the form of recombinant protein or by gene transfer, to 
promote the development of additional collateral blood vessels that would act like 
endogenous conduits of bypass around the occluded native arteries; a strategy known as 
therapeutic angiogenesis. This strategy has demonstrated to increase the tissue perfusion by 
means of neovascularization in a considerable number of preclinical tests of ischemia. In 
patients with critical ischemia of the lower extremities or with coronary terminal arterial 
disease, the clinical tests have demonstrated a symptomatic improvement and have 
contributed new objective evidence of improvement in perfusion, suggesting that this 
strategy can constitute an alternative method for treatment in patients in whom the 
therapies available at the moment have failed or they are not viable. The next targets of the 
research in the field of angiogenesis are going to be to determine the optimal dose, the 
formulation, the route of administration and the combination of growth factors; to 
determine the needs of endothelial progenitor cells or the supplementation with stem cells; 
to provide an effective and safe therapeutic angiogenesis, as well as to adapt the 
angiogenesis to the individual needs of the patients.  
Among the strategies to induce angiogenesis various growth factors have been used 
including the vascular endothelial growth factor (VEGF), the angiopoietines, the fibroblastic 
growth factor (FGF), the hypoxia-inducible factor-1α (HIF-1α), the monocyte chemotactic 
protein-1 of (MCP-1), the hepatic growth factor (HGF), and the stimulating factor of colonies 
of granulocytes and macrophages (GM-CSF). The strategy consists of transferring the genes 
that codify for some of the above proteins to the target tissue, favoring the development of 
neovascularization in the ischemic myocardium. In preclinical animal models this approach 
has demonstrated to be effective promoting the growth and generation of new capillaries, 
although the relevance for the myocardial tissue has not been evaluated (Shen & Vatner, 
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1995; Wijns et al., 1998). It has been shown that with an expression for more than 4 weeks 
the newly formed vessels undergo a tissue remodeling that allows them to remain even 
though the stimulus is no longer present.  
There is increasing evidence that VEGF is the master regulator of angiogenesis and thus is 
the prototype of angiogenic growth factors for gene therapy (Yla-Herttuala & Alitalo, 2003; 
Yla-Herttuala et al., 2007). In animal models with HF secondary to myocardial ischemia, 
administration of gene therapy for angiogenesis using VEGF has been associated with an 
improvement of the myocardial perfusion after 3 weeks of administration, and the 
myocardial function was also improved. The angiogenesis induced by gene therapy, is one 
of the more explored strategies at present, to treat CVD in humans, up to date with more 
than 15 different clinical trials of phase 1 already completed and many clinical trials of phase 
2/3 are ongoing using adenoviral gene therapy in patients with coronary artery disease, 
with different goals, including therapeutic angiogenesis to improve the myocardial 
perfusion, the prevention of re-stenosis of stents, the prevention of the fault of venous grafts 
in revascularization, however, the results obtained are difficult to interpret, mainly due to 
the variation among the used vectors, the therapeutic routes of administration and the 
targets (Zachary & Morgan, 2011). Besides, one of the problems to consider is that the 
efficiency of the transference of genes is reciprocal to the size of the guest, partly by the 
limited diffusion of the vector in a greater amount of tissue. For this reason although several 
studies are promising in animal models, the results could be difficult to reproduce in 
humans.  
Most of the cardiovascular gene therapy trials have been designed to study therapeutic 
blood vessel growth. The use of therapies using recombinant VEGF, FGF-2 and granulocyte 
macrophage colony-stimulating factor proteins has been researched in peripheral and 
myocardial ischemia, but there were no clear improvements in the clinical outcome of the 
patients (Henry et al., 2003; Lederman et al., 2002; Lederman et al., 2001). Several VEGF gene 
therapies using naked DNA have been tested by intramyocardial injection or 
percutaneously into the ischemic myocardium with the NOGA catheter or via thoracotomy 
alleviated angina and reduced the area of ischemic myocardium (Reilly et al., 2005; Vale et 
al., 2001).  
Some gene therapy clinical trials using FGF have been reported. In the phase 1/2 AGENT-1 
trial, intracoronary administration of AdFGF-4 improved exercise time at 4 weeks in stable 
angina pectoris patients (Grines et al., 2002).  Similarly, in the phase 2 AGENT-2 trial, was 
observed a reduction of the myocardial ischemic area (Grines et al., 2003).  Nevertheless, the 
results obtained from the gene therapy clinical trials performed to date verify that gene 
therapy is a strategy with viability to treat patients who are not susceptible to be treated 
with more conventional alternatives. 
Another potential target for gene therapy in CHD is the injury generated by oxidative stress, 
mainly observed in myocardial infarction and ischemia-reperfusion injury. The central point 
is the generation of reactive oxygen species, which produce lipid and protein oxidation, and 
also interact with several calcium handling proteins, leading to an augmented entry of 
calcium into the cell and a secondary elevation of intracellular concentration, which leads to 
cellular injury (Cantor et al., 2003; Dhalla et al., 2000; Maddika et al., 2009). Among the 
targets to prevent oxidative stress, is the over expression of the extracellular superoxide 
dismutase (Ec SOD), which has a central antioxidant role, has been tested pre-emptively in 
animals later subjected to myocardial infarction and it was observed that mimicking 
myocardial ischemic preconditioning, it leads to decreased infarct size (Agrawal et al., 2004; 
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Li et al., 2001). The Thioredoxins (Trx) are proteins that have a potent antioxidant role and 
protect against oxidative stress by decreasing the superoxide anion generation and 
interacting with intracellular signalling pathways as p38MAPK (Tao et al., 2006). In mice 
models of CHD and myocardial infarction, the over-expression of the Trx-1 gene has an 
angiogenic effect, decreases apoptosis and reduces the ventricular remodelling (Adluri et al., 
2011; Samuel et al., 2010), thus the use of Trx as a potential target is exciting and guarantees 
further research. Finally, it has been demonstrated that nitric oxide has a protective role in 
myocardial infarction minimizing oxidative stress, in mice the transfer of adenoviral 
delivered nitric oxide synthase previous to the generation of an infarction, results in reduced 
infarct size, improved contractility and ventricular function. It also decreases the 
inflammation in the infracted area and decreases phosphorylation of the MAPK overall 
improving the outcome of the treated mice (Chen et al., 2010; Jones et al., 2004b). 
As mentioned previously, cell survival and apoptosis plays a key role in the chronic 
evolution of CHD, after a myocardial infarction or chronic ischemia, some surviving cells 
will start apoptosis and lead to ventricular remodeling and deterioration of the function, we 
have previously mentioned the role and potential target of the MAPK pathway and Bcl-2. 
The use of heat shock proteins, specifically HSP72 over-expression, in rats subjected to 
ischemia-reperfusion injury, resulted in decreased levels of apoptosis, increased activity of 
intracellular antioxidant systems, increased levels of Bcl-2, thus showing a cardioprotective 
effect (Suzuki et al., 2002). Also the use of the troponin I type 3 interacting kinase (TNNI3K) 
a member of the MAP kinase family with angiogenic and myogenic roles, has been explored 
combined with cellular therapy, over expressing it on pluripotent progenitor cells, which are 
then transferred into infarcted mice hearts, the results show a decrease infarction injury, 
decreased remodeling, induction of myogenesis and inhibition of p38-JNK mediated 
apoptosis (Lai et al., 2008).  
7. Arrhythmias 
Cardiac arrhythmias constitute a significant cause of morbidity, and sudden cardiac death 
primary o secondary to other cardiac diseases constitutes the main cause of death in CVD.  
While most are susceptible to pharmacological treatment, these therapies have a global 
effect in the heart, meaning that while it has the desired effect on the affected region of the 
heart, it also modifies the behavior of other regions and may even have a pro-arrhythmic 
effect. It must also be mentioned that a number of cardiac arrhythmias are caused by genetic 
causes, and as previously mentioned these constitute the most obvious targets for gene 
therapy, but only a small number of arrhythmias have a monogenic origin. 
While the vectors used in arrhythmia treatment follow the same principles as in other CVD, 
delivery constitutes a significant problem. Direct myocardial injection is limited due to the 
size, location and thickness of the atria. Intracoronary perfusion is suboptimal since the atria 
vasculature is not as well defined as that of the ventricles. At this time the most effective 
method of gene delivery in an experimental setting is known as epicardial gene panting, 
where a solution containing the vector, a polymerization compound and a diluted protease 
are applied over the surface of both atria, obtaining full wall thickness transfer (Kikuchi et 
al., 2005).  
Atrial fibrillation (AF) is the most common arrhythmia encountered. In the United States 
only, AF affects 2-5 million people and it has an increasing incidence. AF may be of primary 
origin, or secondary to structural disease; while in the former case it is due to electrical 
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imbalances, in the latter is mainly to atrial remodeling with fibrosis of the atria and 
remodeling (Benjamin et al., 1998). Thus it is mainly the primary AF which has been 
explored as a potential target for gene therapy. Therapeutic strategies in AF are to 
controlling cardiac rate or restoring sinus rhythm. Primary AF is an abbreviation of action 
potential duration and, therefore, refractory period. This provides the substrate for 
abbreviated reentrant wavelengths, which serve to stabilize the chaotic atrial electrical 
activity. 
One approach that has been explored for restoring sinus rhythm is the use of a dominant 
negative mutant potassium channel KCNH2-G628S that blocks the ion channel pore region. 
The transfer of an adenoviral vector by epicardial painting in a pig model of AF, a 
significant prolongation of the monophasic action potential was observed, with a reversal of 
AF observed (Amit et al., 2010). These results constitute a significant pathway to be 
explored. A second approach researched mimics the rate control; a mutated constitutively 
active inhibitory G protein in a viral vector is transferred to pigs with induced AF, and a 
20% decrease on the maximal ventricular rate is observed (Bauer et al., 2004; Donahue et al., 
2000).  
The ventricular arrhythmias (VT) constitute a significant cause of death in several CVD, they 
have been mainly attributed to the beat-to-beat variation of the action potential. The 
proposed mechanisms underlying these variations are alterations of ionic currents or of the 
calcium cycling, with a slop clearing of calcium during the relaxation. In hearts where a viral 
vector expressing SERCA2 is transferred, the susceptibility of mice hearts to ventricular 
arrhythmias after rapid pacing is decreased (Cutler et al., 2009). One of the most relevant 
groups in the VT spectrum are those secondary to myocardial ischemia and infarction. One 
of the probable mechanisms of this type of VT is the slow conduction due to altered gap 
junction expression and reduced velocity of the action potential. One of the proposed 
mechanisms for velocity is a more positive resting membrane potential in scar border 
myocytes, secondary to an inactivation of some of the sodium current carried by the Nav1.5 
(SCN5A) channel. To correct these alterations, the transfer of a skeletal muscle sodium 
channel has been tested in a canine post-MI model, observing a significant reduction of 
induced VT (Lau et al., 2009). MicroRNAs have also been explored as targets for the 
treatment of VT, in post-MI hearts miR-1 is up-regulated, with a subsequent inhibition of the 
expression of ion channels, when antagomirs are transferred, a decrease of the arrhythmic 
potential is observed (Yang et al., 2007). 
An increasing trend observed in an ageing population is the increasing incidence of bradi-
arrhythmias. An abnormal generation of the electrical impulse in the atria (sinus node 
dysfunction) or its propagation to the ventricles (atrioventricular [AV] block) may result in 
the development of abnormally slow heart rate, and in most of the cases the only 
satisfactory option is the implantation of a definitive pacemaker. Pacemaker implantation 
lacks sufficient physiological feedback parameters to grant greater freedom to the recipient. 
Other disadvantages are the mechanical nature of the treatment and associated risks. The 
experimental approaches for bradi-arrhythmias are focused on altering the function of 
existing cardiomyocytes. 
The basis of the treatment of bradi-arrhythmias, has been focused on reducing the diastolic 
repolarization currents by inhibiting diastolic currents, the approach described  suppresses 
the diastolic entrance of potassium by transferring a mutant inactive channel of Kir2.1, 
afterwards a new ventricular activity is observed (Miake et al., 2002). Another alternative 
researched is the combination on gene and cell therapy, where mesenchymal stem cells were 
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electroporated with plasmid DNA of HCN2, and latter injected into the anterior wall of 
dogs who had previously been subjected to ablation of the AV node; after 10 days 
spontaneous ventricular activity was observed (Plotnikov et al., 2007). 
Thus as we have briefly exposed, gene therapy for arrhythmias is an exciting field which has 
shown encouraging and promising results, but it is also true that is probably one of the 
fields in CVD, that is most distanced form a translational setting. With he current pace of 
research it is certainly a field to keep a close watch on the next years. 
8. Vein graft disease 
Myocardial revascularization either by coronary artery bypass graft surgery (CABG) or 
percutaneous transluminal coronary angioplasty (PTCA) has became the standard of care 
for ischemic heart disease; both techniques are highly successful and have significantly 
improved its prognosis. However both have significant long-term issues with their 
durability, in the case of CABG, it is due to the patency of graft used, while arterial grafts 
have an excellent long term patency, saphenous vein graft (SVG) are still widely used due to 
technical considerations. SVG are a useful and valid tool in CABG but their long term 
patency is impaired by what is known as vein graft disease (VGD), where a proliferation of 
smooth cells and endothelial cells lead to intimal hyperplasia, which gradually decreases the 
patent lumen of the graft. Conventional treatments can help to prevent VGD, but still 
constitutes a significant problem in surgically revascularized patients with coronary artery 
disease (Parang & Arora, 2009). 
Thus VGD is another entity which may be susceptible to be treated by gene therapy, one of 
the main advantages when using gene therapy in this disease is the possibility of delivering 
the therapy ex vivo, after the graft has been harvested. The pathogenesis of it, results from 
the graft’s adaptation to high pressure and the loss of inhibition of the endothelial layer, 
there is a proliferation and migration to the intima of smooth muscle cells. These cells 
release cytokines and degrade the surrounding matrix, creating an inflammatory 
environment, highly atherogenic. In the hyperplasia of the intima the E2F transcription 
factors have been identified as key in initiating it. A decoy oligonucleotide for E2F has been 
designed and tested successfully in animal models, a phase 3 clinical trial was designed to 
test its efficacy in preventing vein graft failure, denominated as the PREVENT IV trial. The 
results did not show a significant decrease in the rate of vein graft failure in the treated 
group; while this specific approach was not successful it has proven that gene therapy is a 
possible approach to VGD (Alexander et al., 2005).  
Another potential target which has only been tested experimentally, is the transfer of the 
fibromodullin gene. As previously mentioned the remodelling of the extracellular matrix 
plays a key role in the genesis on intimal hyperplasia, here widely known proteins have 
been identified, one of them is TGF-β1, fibromodullin and decorin are leucine rich-
proteoglycans, which possess TGF-β1 antagonist activity in vitro and in vivo. Adenoviral 
transfer of the fibromodullin gene to harvested human saphenous veins, revealed 
significantly reduced neointimal thickness (Ranjzad et al., 2009). This proves that while 
clinical trials have been unsuccessful in the past, there are still a number of target that can be 
researched in the future and may result in an effective gene therapy option for VGD. 
8.1 Intra-stent restenosis 
As mentioned PTCA is widely used in the treatment of coronary artery disease, briefly an 
atherosclerotic obstruction of the coronary vessel is identified and dilated with a high 
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pressure balloon, afterwards a metal stent is deployed to prevent new obstructions. As in 
CABG its main drawback it’s the long-term patency of treated lesions, a similar phenomena 
is observed where a neointimal proliferation results in the restenosis of the stent. Currently 
the most used option to prevent this restenosis is the use of drug eluting stents, which are 
covered in different drugs that inhibit the neointimal proliferation. However there is still a 
high number of stents that will develop restenosis. This particular field presents another 
option for the delivery of gene therapy, by deploying gene-delivering stents.  
Intrastent restenosis has been researched in animal models, one of the strategies involves the 
inhibition of cellular proliferation using the CREB binding protein, which is known as a 
regulator of cell proliferation and apoptosis in vascular endothelial and smooth muscle cells. 
Rats were subjected to endothelial injury and denudation of the carotid artery, afterwards 
the injured artery was treated with lentivirus expressing siRNA for CREB binding protein; 
after 4 weeks it significantly decreased the neointimal formation. Thus providing a new 
target to be researched in the future (Yang et al., 2010). Another researched strategy is the 
use of stents delivering the gene of the endothelial nitric oxide synthase (eNOS); it is well 
describe that NO is a critical molecule in the vessel wall as it is responsible for a variety 
functions including inhibition of platelet adhesion and aggregation, inhibition of leukocyte 
chemotaxis, inhibition of smooth muscle cell growth and migration, vasodilatation, and re-
endothelialization, thus making it a very attractive target to prevent neointimal hyperplasia. 
In a rabbit model of intrastent restenosis gene-eluting stents which delivered eNOS had 
significantly less neointimal formation, also it is important to mention, that in this study the 
gene was delivered by a lipid based transfection instead of a viral vector.  
9. Conclusions  
Despite of the therapeutic advances CVD continue to be the main cause of morbidity and 
mortality in the world; gene therapy appears to be a promissory alternative, having the 
capacity to correct the observed fundamental defects in several CVD. Currently gene 
therapy is an area of basic and clinical research of great significance that should produce 
positive results for HF in the next few years. An increase in the knowledge of the underlying 
molecular mechanisms of HF, along with advances in gene therapy technology has led to 
important efforts in in vitro studies and pre-clinical testing of a number of gene targets and 
recently in the successful completion of the first phase 2 gene therapy trial for HF. More-
over, the safety of AAV vectors has been demonstrated for the treatment of HF combined 
with the efficacy of the use of SERCA2a in the treatment of HF, thus opening the field for 
testing new targets to modulate with more advanced vector systems for gene therapy. As 
we have briefly exposed, myocardial ischemia along with HF constitutes one of the most 
researched fields in the CVD spectrum, and probably is the area where gene therapy has 
advanced further, and it even has several pre-clinical and clinical studies, and while the 
results are still non conclusive and even in some cases discouraging, it only shows the many 
difficulties and the need for further research, before gene therapy can be established as an 
everyday available clinical tool. It must also be said that there is a need to diversify the 
efforts in research, since in the case of IHD most of it has focused on angiogenesis, while the 
other pathways as ischemia reperfusion injury and apoptosis have been only scratched in 
the basic setting, thus more research is needed in areas which can offer new and exciting 
promising targets for gene therapy. One of the majors obstacles that presents the basic 
research and clinical application of this and other therapeutic options, is the complexity of 
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the underlying mechanisms, and as such it is required that these along with the indications 
are known and understood so that we can be able to explode to the maximum the new 
capacities that this therapeutic option offers, reason why is necessary to closely follow the 
advances in this field in the near future. 
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